Cancer Immunology Reserch

Targeting of tumoral NAC1 mitigates myeloid-derived suppressor cell-mediated immunosuppression and potentiates anti-PD-1 therapy in ovarian cancer

by

Cancer Immunol Res. 2024 Nov 12. doi: 10.1158/2326-6066.CIR-24-0084. Online ahead of print. ABSTRACT Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer with a low rate of response to immunotherapy such as immune checkpoint blockade (ICB) therapy. Here, we report that nucleus accumbens-associated protein 1 (NAC1), a putative driver of EOC, has … Read more

Inflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted and immunotherapy

by

Cancer Immunol Res. 2024 Nov 11. doi: 10.1158/2326-6066.CIR-24-0561. Online ahead of print. ABSTRACT Anti-PD-1, trastuzumab, and chemotherapy are used in the treatment of patients with advanced HER2-positive esophagogastric adenocarcinoma (EGA), but long-term survival remains limited. Herein, we report extended follow-up data from the INTEGA trial (NCT03409848), which investigated the efficacy of the anti-PD-1 nivolumab, trastuzumab, … Read more

Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma

by

Cancer Immunol Res. 2024 Nov 8. doi: 10.1158/2326-6066.CIR-24-0324. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of unresectable hepatocellular carcinoma (HCC), but their impressive efficacy is seen in just a fraction of patients. One key mechanism of immunotherapy resistance is the paucity of dendritic cells (DCs) in liver malignancies. Here, … Read more

Alternate MHC I antigen presentation pathways allow CD8+ T-cell recognition and killing of cancer cells in the absence of ß2M or TAP

by

Cancer Immunol Res. 2024 Nov 1. doi: 10.1158/2326-6066.CIR-24-0320. Online ahead of print. ABSTRACT Major histocpmpatibilty complex class I (MHC I) antigen presentation allows CD8+ T cells to detect and eliminate cancerous or virally infected cells. The MHC I pathway is not essential for cell growth and viability and consequently cancers and viruses can evade control … Read more

BTN2A1: A Novel Target to Boost Tumor Killing Capacity of Human γδ T Cells

by

Cancer Immunol Res. 2024 Oct 30:OF1. doi: 10.1158/2326-6066.CIR-24-0925. Online ahead of print. ABSTRACT γδ T cells have recently raised great interest as effector cells in cancer immunotherapy because of their HLA-independent mode of action and their broad tumor reactivity. To translate the application of γδ T cells into clinically effective immunotherapies, specific tumor targeting and/or … Read more

Gefitinib Reverses PD-L1-Mediated Immunosuppression Induced by long-term Glutamine blockade in Bladder Cancer

by

Cancer Immunol Res. 2024 Oct 29. doi: 10.1158/2326-6066.CIR-24-0039. Online ahead of print. ABSTRACT Glutamine is a major energy source for tumor cells and blocking glutamine metabolism is being investigated as a promising strategy for cancer therapy. However, the antitumor effect of glutamine blockade in bladder cancer remains unclear, necessitating further investigation. Here, we demonstrated that … Read more

CD27-Armored BCMA CAR T Cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial

by

Cancer Immunol Res. 2024 Oct 21. doi: 10.1158/2326-6066.CIR-24-0051. Online ahead of print. ABSTRACT B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM); however, whether patients have long-term response has yet to be established. We investigated the feasibility of CBG-002, an … Read more

Preclinical development of T cells engineered to express a T cell antigen coupler (TAC) targeting Claudin 18.2-positive solid tumors

by

Cancer Immunol Res. 2024 Oct 15. doi: 10.1158/2326-6066.CIR-24-0138. Online ahead of print. ABSTRACT The T cell antigen coupler (TAC) is a chimeric receptor that facilitates tumor antigen-specific activation of T cells by co-opting the endogenous T cell receptor complex in the absence of tonic signaling. Previous data demonstrates that TAC affords T cells with the … Read more

T cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL-1 and TNFα Inflammation

by

Cancer Immunol Res. 2024 Oct 15. doi: 10.1158/2326-6066.CIR-24-0416. Online ahead of print. ABSTRACT Resistance to immune checkpoint inhibitors (ICIs) is common, even in tumors with T cell infiltration. We thus investigated consequences of ICI-induced T cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in … Read more

Complement factor H is an ICOS ligand modulating Tregs in the glioma microenvironment

by

Cancer Immunol Res. 2024 Oct 10. doi: 10.1158/2326-6066.CIR-23-1092. Online ahead of print. ABSTRACT The survival rate of glioma patients has not significantly increased in recent years despite aggressive treatment and advances in immunotherapy. The limited response to treatments is partially attributed to the immunosuppressive tumor microenvironment, where regulatory T cells (Tregs) play a pivotal role … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri error code: 520